Barclays & Lazard Capital Upgrade Human Genome Sciences (HGSI)
HGSI Hot Sheet
Rating Summary:7 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Barclays upgrades Human Genome Sciences (Nasdaq: HGSI) from Equalweight to Overweight
Lazard Capital also upgrades Human Genome Sciences from Hold to Buy.
To see more analyst ratings on HGSI Click Here.
Human Genome Sciences (HGS) is a commercially focused biopharmaceutical company.
Lazard Capital also upgrades Human Genome Sciences from Hold to Buy.
To see more analyst ratings on HGSI Click Here.
Human Genome Sciences (HGS) is a commercially focused biopharmaceutical company.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- TD Securities Upgrades Rogers Communications (RCI) to Buy; Negatives Priced In
- UPDATE: UBS Upgrades Assured Guaranty (AGO) to Buy; Opportunity Opens After Recent Dip on Moody's Review
Create E-mail Alert Related Categories
UpgradesRelated Entities
Lazard, BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
